J&J Psoriasis Drug Might Pose Risk: FDA Staff

Law360, New York (June 16, 2008, 12:00 AM EDT) -- Medical review staff at the U.S. Food and Drug Administration have raised the possibility that long-term use of ustekinumab, an experimental treatment for psoriasis from Johnson & Johnson, could increase the risk of cancer.

In documents prepared for a meeting of the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on Tuesday, June 17, the FDA staff said that there were no clinical studies showing a correlation between long-term ustekinumab treatment and cancer, but that “[d]ue to the mechanism of action of ustekinumab ... there is a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.